<DOC>
	<DOCNO>NCT00150657</DOCNO>
	<brief_summary>- study do find combination carboplatin gemcitabine effective treatment advance lung cancer bevacizumab , agent block tumor blood vessel formation , add - study measure time progression patient treated combination ; hope show addition bevacizumab improve time progression ( increase amount time disease begin worsen ) - patient receive three drug ; placebo</brief_summary>
	<brief_title>Study Carboplatin/Gemcitabine Plus Bevacizumab Advanced Lung Cancer</brief_title>
	<detailed_description>- Patients advanced ( stage IV , Stage IIIB effusion ) non-small cell lung cancer non-squamous histology , good performance status , adequate organ function eligible . - Patients brain metastasis , squamous histology , hemoptysis exclude . - All patient must give informed consent . - Schema gemcitabine 1250 mg/M2 IV day 1,8 carboplatin AUC 5 IV day 1 bevacizumab 15 mg/kg IV day 1 repeat every 21 day 6 cycle</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically proven nonsmall cell lung cancer , newly diagnose recurrent previous surgery and/or radiation therapy Stage IV disease stage IIIB malignant pleural effusion measurable evaluable disease Performance status 0 1 ( ECOG ) adequate renal , hepatic , bone marrow function adequate recovery previous surgery radiotherapy inform consent brain metastasis squamous ( epidermoid ) histology hemoptysis central airway disease Pancoast tumor previous chemotherapy biologic therapy lung cancer prior malignancy within previous 5 year except nonmelanoma skin cancer cervical CIS pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>